Deciphera’s Vimseltinib Could Benefit From Liver Safety, Prescriber Overlap in TGCT

Positive topline results from the Phase III MOTION trial showed none of the liver toxicity that earned Daiichi Sankyo’s Turalio a boxed warning and REMS in tenosynovial giant cell tumor.